Schedule II is doing more harm than good

Stimulant medications are currently Schedule II, which is the same legal category as fentanyl, oxycodone, and morphine.

Stimulant medications are currently Schedule II, which is the same legal category as fentanyl, oxycodone, and morphine. Stop and read that sentence again because it’s genuinely insane that we’re still doing this in 2026. The categorization comes from the Controlled Substances Act of 1971, written before adult ADHD was a recognized clinical entity, before telehealth existed, before electronic prescribing, before basically any of the conditions that make this scheduling decision relevant. The category hasn’t been revisited in any meaningful way in fifty-four years, and the result is a regulatory framework that costs stable patients an enormous amount of friction without doing much to prevent the diversion or abuse it was supposedly designed to prevent. Schedule III is the right home for stimulants. The case for moving them is straightforward, the DEA knows it, and they’re going to keep not doing it for reasons that have basically nothing to do with science and everything to do with bureaucratic inertia.

What Schedule II actually means in practice

Schedule II prescriptions cannot be phoned in (well, post-2023 they technically can in some emergency cases, but in practice they aren’t, the workflow doesn’t really support it). They cannot have refills. Every month the patient needs a new prescription, which means an interaction with the prescriber, a new electronic transmission to the pharmacy, and a fill that has to happen within a tight window or the prescription expires and the whole thing starts over again.

The DEA caps annual production through a quota system that’s the direct cause of the Adderall shortage there’s a separate post on. Out-of-state filling is restricted. Mail-order is restricted but not forbidden… I order patient stimulants from mail-order pharmacies routinely and I get my own from one, it’s narrower than for a Schedule III drug but it’s not the no-go the rules make it sound. Early fills are restricted. Pharmacy stocking is itself restricted because pharmacies don’t want to keep large inventories of Schedule II drugs on hand… the regulatory paperwork around it is a nightmare and the DEA can show up to audit at any time, which is the kind of thing that makes a pharmacy manager’s blood pressure go up looking at the order screen.

For a guy on Vyvanse for adult ADHD who’s been stable for years… working, paying his bills, raising his kids, refilling the same prescription every thirty days… this is a lot of friction. He has to remember to request the refill. The prescriber has to send it. The pharmacy has to have it. The window has to align. If any of those four things breaks, he goes without his medication, and any guy who’s been on a stimulant for more than a year can tell you that those four things break regularly.

What Schedule III means in practice

Schedule III drugs can be phoned in, can have refills (up to five within six months), aren’t quota-capped, can be mailed, and impose much less regulatory drag on pharmacies. Testosterone is Schedule III. Ketamine is Schedule III. Buprenorphine is Schedule III. Codeine combinations are Schedule III. The agency has plenty of experience managing controlled substances at this category without the world ending or any of the parade-of-horribles diversion scenarios materializing.

Marijuana was moved from Schedule I to Schedule III in 2024 on the basis that the Schedule I categorization didn’t match the abuse and dependence data. Stimulants fit Schedule III much better than they fit Schedule II by any honest measure: abuse potential, dependence liability, how useful they actually are for the people taking them. The case for moving them is an easier case than the one made for moving marijuana, which is a sentence I never expected to be typing in a blog post but here we are.

The historical context

When stimulants got classified Schedule II in 1971, the cultural picture of stimulants was different in every important way. Methamphetamine abuse in the 60s and early 70s. The diet-pill epidemic. The post-war benzedrine problem. The categorization was a political response to a specific moment, not a careful weighing of how risky the drug actually is versus how much good it does… it made political sense in 1971 in the same way that a lot of things made political sense in 1971 that we’d be embarrassed about now.

The diagnostic landscape since then has shifted dramatically. Adult ADHD wasn’t formally recognized in the DSM until 1994. The bulk of legitimate stimulant prescribing in 2026 happens for indications that didn’t exist as recognized clinical entities when the law was written, which is the kind of thing the regulatory framework would ideally update for, except regulatory frameworks don’t really update for anything unless somebody important is yelling about it, and nobody important is yelling about this.

The diversion argument (taking it seriously)

The case for keeping stimulants Schedule II is that the tight regulatory framework prevents diversion, which is the technical term for slinging pills to or from a friend or friendly dealer… not a good idea by the way, if you actually have ADHD just get a prescription. I want to take the diversion argument seriously here because it’s the strongest argument the DEA has and I don’t want to brush past it pretending the issue doesn’t exist.

Diversion happens. Some prescribed stimulants do end up being shared or sold, particularly among college students, and the diversion rates from research that’s actually been done are in the five-to-fifteen-percent range of prescribed users diverting at some point… most of that being giving or selling a pill to a roommate rather than ongoing trafficking. That’s not zero, and I’m not pretending it is. The question is whether the regulatory cost of Schedule II is being paid by the right people, and the answer is no, it’s being paid by the eighty-five to ninety-five percent of patients who aren’t diverting, in exchange for friction that probably reduces diversion at the margins, in exchange for shortages that affect everybody.

The other thing about the diversion argument is that the actual abuse driver in the United States right now is not pharmaceutical stimulants, it’s illicit methamphetamine, which exists at industrial scale entirely outside the prescription system. Tightening the prescription framework does nothing to affect the illicit market. It just affects the patients with prescriptions, which is the wrong patients to be affecting if your stated goal is reducing harm.

What the friction actually costs

Patients miss doses. Treatment outcomes get worse. Some people give up on stimulant treatment entirely, which is a real medical cost that nobody’s measuring because there’s no line item on a spreadsheet for “the patient who decided the pain in the ass of dealing with his ADHD wasn’t quite as bad as the pain of dealing with the pharmacy every month.” Pharmacy infrastructure runs on a regulatory model that adds cost to every single Schedule II prescription. Prescribers like me spend time on monthly refill paperwork that could be spent on patient care. The annual quota system creates shortages we’re currently in year four of, and somehow this is fine, apparently.

The friction doesn’t appear to reduce the actual rates of stimulant-involved overdose or addiction, which are low to begin with relative to the population on prescribed stimulants and which would not be meaningfully affected by Schedule III either way. The CDC overdose data doesn’t show stimulant-prescription-related overdose as a major mortality driver. The opioid crisis was a Schedule II crisis, sure, but it wasn’t a stimulant crisis, despite both being Schedule II, which suggests the schedule itself isn’t doing the work the DEA pretends it’s doing.

What moving to Schedule III would actually change

Quotas would go away, which would resolve the shortage. Refills would be allowed, which would reduce monthly prescribing burden enormously. Out-of-state filling and mail-order would be easier, which matters for patients in rural areas and patients who travel for work. Pharmacy stocking would improve because of reduced regulatory drag.

What wouldn’t change: the requirement that a prescriber actually evaluate the patient before prescribing. The clinical responsibility doesn’t move. The standards of care don’t move. The pharmacovigilance doesn’t move. The DEA still has authority over manufacturing and prescriber registration. The change is in the layer of friction the law adds on top of clinical practice, not in the clinical practice itself, which is a distinction the DEA’s public statements about this tend to elide.

What this actually costs in time

People on a stable stimulant prescription spend somewhere between thirty and sixty minutes a month on the logistics of it. Calling the office for the refill. Picking it up in the window. Dealing with the months it isn’t in stock at their usual pharmacy. Six to twelve hours a year of someone’s actual life on regulatory friction for a stable medication… and that’s for the patients who actually do the math. None of that friction stops a guy who wants to divert from doing it. None of it prevents an addict from finding methamphetamine on the street. It just makes life harder for the paramedic, the welder, the software engineer, the guy who needs his medication to do his job.

What’s actually likely to happen

Schedule III rescheduling for stimulants is being talked about in some advocacy circles and in a handful of academic papers, but it’s not on any active legislative or regulatory track that I’m aware of. The DEA has shown no appetite for it. Congress has shown no interest. The pharmaceutical industry has no real incentive to push for it because the current system doesn’t actually hurt their bottom line… if anything the artificial scarcity created by quotas helps them with pricing, which is the kind of thing nobody says out loud.

The most likely path forward is a series of incremental fixes that don’t change the underlying problem. Quota bumps that don’t keep pace with demand. Telehealth flexibility extensions that get periodically threatened. Enforcement actions against the most visible bad actors. Patients continuing to lose hours of their lives to a regulatory framework that was written for a different country and a different problem, and that nobody with the authority to fix has any real motivation to fix.

Schedule II made political sense in 1971 in the same way that a lot of things made political sense in 1971 that we’d be embarrassed about now.

Bottom line

The classification was written in 1971 for a different problem, and the problem it was written for is not the problem it’s currently solving, or failing to solve. Moving stimulants to Schedule III would resolve most of the shortage, reduce friction for stable patients, and not meaningfully change the actual diversion or overdose picture in either direction. It’s a policy fix that’s overdue, and the reason it isn’t happening has very little to do with whether it’s the right call clinically.